Jupiter Neurosciences Receives Nasdaq Deficiency Notices, Faces Delisting

Jupiter Neurosciences, Inc. ( (JUNS) ) has provided an update.

On February 26, 2026, Jupiter Neurosciences disclosed it had received two Nasdaq deficiency notices, stating its shares had closed below the $1.00 minimum bid price and its market value of listed securities had fallen under the $35 million threshold for the prior 30 consecutive business days. The company has until August 25, 2026, to regain compliance with both standards—through sustained improvements in share price and market value—and may face potential delisting or need for measures such as a reverse stock split if it cannot satisfy the requirements, though its stock continues to trade normally while it evaluates options and informs investors via its website and social media channels.

The most recent analyst rating on (JUNS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Jupiter Neurosciences, Inc. stock, see the JUNS Stock Forecast page.

More about Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc. operates in the biopharmaceutical sector, focusing on neurological conditions and related therapeutic developments. The company’s common stock trades on The Nasdaq Capital Market under the ticker JUNS, giving it access to public equity markets to fund its operations and research initiatives.

Average Trading Volume: 281,122

Technical Sentiment Signal: Strong Sell

Current Market Cap: $20.57M

Find detailed analytics on JUNS stock on TipRanks’ Stock Analysis page.